PET/CT to Identify "Vulnerable" Arterial Plaque

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2006 by Rambam Health Care Campus.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT00416065
First received: December 26, 2006
Last updated: NA
Last verified: November 2006
History: No changes posted
  Purpose

The purpose of this research is to evaluate the presence, location and intensity of FDG uptake in the large arteries using the new technology of fused PET/CT imaging and to compare FDG uptake with the presence of arterial calcifications as seen on the simultaneously acquired CT, in order to determine if FDG was increases incalcified plaque or in a different location in the arterial wall. we will also evaluate the relationship between FDG localization and future cardiovascular events in out patient population


Condition Intervention
Cancer
Device: PET/CT imaging

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: PET/CT to Identify "Vulnerable" Arterial Plaque

Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:
  • the impact of the imaging modality on patient management

Secondary Outcome Measures:
  • the impact of the imaging modality on patient management

Estimated Enrollment: 800
Study Start Date: April 2004
  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients referred for clinical FDG-PET/CT studies
  • Patients 50 yr or older
  • Patients signed informed consent

Exclusion Criteria:

  • Patients unable or unwilling to tolerate the scan until its completion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00416065

Contacts
Contact: Ora Israel, MD 972-4-8543009 o_israel@rambam.health.gov.il

Locations
Israel
Rambam Medical Center Recruiting
Haifa, Israel
Contact: Ora Israel, MD    972-4-8543009    o_israel@rambam.health.gov.il   
Sponsors and Collaborators
Rambam Health Care Campus
Investigators
Principal Investigator: Ora Israel, MD Rambam Health Care Campus
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00416065     History of Changes
Other Study ID Numbers: plaqueCTIL
Study First Received: December 26, 2006
Last Updated: December 26, 2006
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

ClinicalTrials.gov processed this record on July 10, 2014